Table 1 Clinical and pathological characteristics

Gender

 Male

36(70.6%)

55(71.4%)

23(63.9%)

 Female

15(29.4%)

22(28.6%)

13(36.1%)

Age (years)

69.10 ± 6.98

68.53 ± 7.29

68.81 ± 6.33

BMI (kg/m²)

24.29 ± 3.67

23.76 ± 2.68

23.25 ± 2.64

ASA-PS

 I

1(2.0%)

2(2.6%)

1(2.8%)

 II

31(60.8%)

54(70.1%)

32(88.9%)

 III

19(37.2%)

21(27.3%)

3(8.3%)

Tumor size (cm)

3.36 ± 0.99

3.69 ± 0.99

3.65 ± 1.01

Histological type

 Adenocarcinoma

45(88.2%)

71(92.2%)

34(94.4%)

 Other

6(11.8%)

6(7.8%)

2(5.6%)

Differentiated degree

 Well /Moderately differentiated

18(35.3%)

31(40.3%)

12(33.3%)

 Poorly differentiated

27(52.9%)

40(51.9%)

22(61.1%)

 Other

6(11.8%)

6(7.8%)

2(5.6%)

Total lymph nodes

15.02 ± 5.47

15.68 ± 7.45

15.36 ± 9.00

Positive lymph nodes

0.24 ± 0.59

0.26 ± 0.66

0.19 ± 0.53

Pathological T stage ^a

 T1

27(52.9%)

44(57.1%)

25(69.4%)

 T2

8(15.7%)

22(28.6%)

5(13.9%)

 T3

3(5.9%)

2(2.6%)

0(0.0%)

 T4

13(25.5%)

9(11.7%)

6(16.7%)

Pathological N stage ^a

 N0

43(84.2%)

66(85.7%)

31(86.1%)

 N1

6(11.8%)

5(6.5%)

3(8.3%)

 N2

1(2.0%)

5(6.5%)

2(5.6%)

 N3

1(2.0%)

1(1.3%)

0(0.0%)

Pathological Stage ^a

 I

30(58.8%)

60(77.9%)

28(77.8%)

 II

10(19.6%)

9(11.7%)

2(5.6%)

 III

11(21.6%)

8(10.4%)

6(16.7%)

 Adjuvant chemotherapy

16(31.4%)

13(16.9%)

6(16.7%)